Writing | Daiki Kumakurahttps://daikikumakura.github.io/feed.xml2026-10-05T09:00:00+09:00Daiki Kumakurahttps://daikikumakura.github.io/タルラタマブの投与間隔を、平均曝露だけで決められるかhttps://daikikumakura.github.io/writing/tcell-engager-regimen-design.html2026-10-05T09:00:00+09:002026-10-05T09:00:00+09:00公開PopPKの個体間変動シミュレーション、有効性の曝露反応、時期別CRS、維持曝露を分けて検討する。平均曝露を合わせてもピークとトラフは保存されないことと、公開情報による判断の限界を示す。When does individual information improve PK/PD prediction?https://daikikumakura.github.io/writing/warfarin-pkpd.html2026-10-04T00:00:00+09:002026-10-04T00:00:00+09:00A reanalysis of measured warfarin PK/PCA data: effect delay, subject-separated prediction, and the limits of using additional PK measurements.Do early tumor measurements improve prediction of subsequent survival?https://daikikumakura.github.io/writing/tumor-dynamics-survival.html2026-10-04T00:00:00+09:002026-10-04T00:00:00+09:00A patient-separated landmark analysis of public colorectal cancer data, including calibration, censoring, uncertainty and temporal-integrity sensitivity.What can aggregate randomized data establish about treatment duration and benefit–risk?https://daikikumakura.github.io/writing/treatment-duration-benefit-risk.html2026-10-04T00:00:00+09:002026-10-04T00:00:00+09:00SCOT trial efficacy and neuropathy compared with endpoint-specific denominators, uncertainty, missingness bounds and limits of joint benefit–risk inference.What changes in paired tumor immune-expression measurements during nivolumab?https://daikikumakura.github.io/writing/on-treatment-immune-change.html2026-10-04T00:00:00+09:002026-10-04T00:00:00+09:00Fixed immune scores in 43 public RNA pairs, with paired change, normalization sensitivity and patient-separated response-association diagnostics.Nimotuzumabの実測PKから考える、曝露比較に必要なモデルの複雑さhttps://daikikumakura.github.io/writing/nimotuzumab-poppk.html2026-10-04T00:00:00+09:002026-10-04T00:00:00+09:00個人別PKから3つのPopPK構造を推定し、内部検証・収束・投与条件の曝露差からモデル採用の限界を検討する。Do two immune-biology scores improve response prediction across urothelial cancer cohorts?https://daikikumakura.github.io/writing/immune-outcome-validation.html2026-10-04T00:00:00+09:002026-10-04T00:00:00+09:00Fixed Teff and stromal features evaluated across public urothelial cancer cohorts, with discrimination, calibration, missingness and transport limits.標的タンパク質分解薬の投与間隔を、最大分解率だけで決められるかhttps://daikikumakura.github.io/writing/er-protac-pkpd.html2026-10-04T09:00:00+09:002026-10-04T09:00:00+09:00ER-PROTACの公開データを点検し、作用部位曝露と標的回復の仮定が投与頻度・PD指標の比較をどう変えるかを最小モデルで調べる。実薬へのfitと臨床用量提案は行わない。タルラタマブの公開PKデータから、投与間隔の変更をどこまで評価できるかhttps://daikikumakura.github.io/writing/tarlatamab-summary-pk.html2026-10-03T00:00:00+09:002026-10-03T00:00:00+09:00公開PK集約値から2コンパートメントモデルを推定し、識別性と不確実性を踏まえてQ2W・Q3W・Q4Wの曝露を比較する。モスネツズマブの公開PopPKモデルを再実装する：段階的増量の曝露比較とRO–CRS外挿の限界https://daikikumakura.github.io/writing/mosunetuzumab-public-pk.html2026-10-02T00:00:00+09:002026-10-02T00:00:00+09:00公開論文と補足資料からmosunetuzumabのPKを再計算。仮想患者2,000例のpaired解析で投与量・間隔の影響を調べ、CD20占有率とCRSに翻訳できる範囲を検討する。図表・Pythonコード・CSV付き。